Plasma genotyping to predict treatment benefit in patients with NSCLC

Go to article

Posted by on April 15, 2016 12:14 pm
Tags:
Categories: health

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies.

Leave a Reply

Your email address will not be published. Required fields are marked *

< Buzz Post home